Novo cuts Wegovy prices, but doctors still see cost challenges for patients
Novo Nordisk is chopping prices again for Wegovy, but doctors say the expense will remain challenging for patients without insurance.
All Stories
Trump unveils deal to expand coverage and lower costs on obesity drugs
President Donald Trump unveiled a deal Thursday with drugmakers Eli Lilly and Novo Nordisk to expand coverage and reduce prices for their popular obesity treatments Zepbound and Wegovy.
Prescription drug coverage options are shrinking for Medicare shoppers
Most markets will still have several stand-alone drug plans, but some options are becoming particularly sparse for shoppers with low-income subsidies.
Pfizer amps up push into obesity treatments with $4.9B deal for Metsera
Five months after ending development of its own obesity treatment, Pfizer is accelerating its push into the rapidly growing field with a nearly $5 billion acquisition.
How to get a COVID-19 shot and ensure it’s covered by insurance
On Friday, vaccine advisers picked by Health Secretary Robert F. Kennedy Jr. declined to specifically recommend the shots but said people could make individual decisions on whether to get them.
Why getting a COVID-19 vaccine is likely to be more complicated this year
A once-straightforward COVID-19 vaccine process has become muddled this year because of new federal guidance on who the shots are approved for.
Expect health insurance prices to rise next year, brokers and experts say
Pricey prescriptions and nagging medical costs are swamping some insurers and employers now. Patients may start paying for it next year.
UnitedHealth says it is under a federal investigation and cooperating
UnitedHealth Group says it is cooperating with federal criminal and civil investigations involving its market-leading Medicare business.
Will you be able to get a COVID-19 shot? Here’s what we know so far.
Want a COVID-19 vaccination this fall? For many Americans, it’s not clear how easy it will be to get one – or if they’ve lost the choice.
Trump administration nixes plan to cover anti-obesity drugs through Medicare
President Donald Trump’s administration has decided not to cover expensive, high-demand obesity treatments under the federal government’s Medicare program.